论文部分内容阅读
目的:观察肾石合剂联合经皮肾镜下钬激光碎石术治疗肾结石的临床疗效。方法:采用随机数字表法将120例肾结石惠者分为观察组和对照组各60例。对照组采用经皮肾镜下钬激光碎石术,术前、术后给予西医常规处理。观察组在对照组治疗的基础上加服肾石合剂。共观察4周。记录首次排石时间、排石过程疼痛程度、采用镇痛药治疗的例数。检测术后1天及术后4周血肌酐(SCr)、尿素(BUN)及肾损伤分子-1(KIM-1)的水平。结果:观察组首次排石时间短于对照组(P<0.01),疼痛程度评分低于对照组(P<0.01),排石过程使用镇痛药的例数少于对照组(P<0.01)。术后4周,2组肾功能指标BUN、SCr和KIM-1均较术后1天下降(P<0.01),观察组BUN、SCr和KIM-1水平均低于对照组(P<0.01)。治愈率观察组为88.3%,对照组为73.3%,观察组治愈率高于对照组(P<0.05)。结论:肾石合剂联合经皮肾镜下钬激光碎石术治疗肾结石,能促进结石的排出,减轻排石过程中患者的疼痛程度,并对患者的肾功能有一定的改善作用,临床疗效显著。
Objective: To observe the clinical efficacy of nephrolithi combined with percutaneous nephrolithotomy holmium laser lithotripsy in the treatment of kidney stones. Methods: A random number table method was used to divide 120 cases of kidney stone beneficiaries into observation group and control group with 60 cases each. The control group was treated with percutaneous nephrolithotomy holmium laser lithotripsy, and western medicine was routinely treated before and after surgery. Observation group in the control group based on the treatment of plus kidney stones mixture. A total of 4 weeks observation. Record the first stone row time, stone row process pain, the number of cases treated with analgesics. The levels of serum creatinine (SCr), urea (BUN) and renal injury molecule-1 (KIM-1) were measured at 1 day and 4 weeks after operation. Results: The time of the first row of stone in the observation group was shorter than that in the control group (P <0.01), and the pain score was lower than that of the control group (P <0.01) . After 4 weeks, the levels of BUN, SCr and KIM-1 in two groups decreased (P <0.01), and the levels of BUN, SCr and KIM-1 in observation group were lower than those in control group (P <0.01) . The cure rate was 88.3% in observation group and 73.3% in control group, and the cure rate in observation group was higher than that in control group (P <0.05). Conclusion: Nephrite combined with percutaneous nephrolithotomy holmium laser lithotripsy for the treatment of kidney stones can promote the discharge of stones, relieve the pain of patients in the row of stones, and to improve the renal function of patients with clinical efficacy Significant.